GlassScriptPhysician profile
Vindhya T Koneru
NPI 1891220612
$18,691.52
in general payments reported to CMS, 2019-2025
41 companies · $2,368 in 2025
The $2,368 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $10K · 2022: $1,679 · 2023: $2,016 · 2024: $2,613 · 2025: $2,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,651 · Travel and Lodging: $341 · Education: $6.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,650.83 |
| Travel and Lodging | $340.92 |
| Education | $6.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $10,780.42 | 2021-2025 | Vercise, General - Dbs |
| Abbvie INC. | $1,436.19 | 2022-2025 | |
| Abbott Laboratories | $1,256.43 | 2022-2025 | Infinity, Eterna, Proclaim |
| Acadia Pharmaceuticals INC | $618.53 | 2022-2025 | Nuplazid |
| Pfizer INC. | $461.65 | 2021-2025 | |
| Merz Pharmaceuticals, LLC | $417.80 | 2022-2025 | Xeomin, Inbrija |
| Lilly USA, LLC | $417.30 | 2022-2025 | Emgality, Amyvid, Kisunla |
| Neurocrine Biosciences, INC. | $399.67 | 2022-2025 | Ingrezza, Ongentys |
| Amneal Pharmaceuticals LLC | $330.57 | 2022-2025 | Crexont, Rytary |
| Sk Life Science, INC. | $283.64 | 2022-2025 | |
| Ucb, INC. | $244.13 | 2023-2025 | Rystiggo |
| Teva Pharmaceuticals USA, INC. | $234.84 | 2022-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Eisai INC. | $191.73 | 2023-2025 | |
| Argenx US, INC. | $167.47 | 2023-2025 | Vyvgart Hytrulo |
| Takeda Pharmaceuticals U.S.A., INC. | $145.88 | 2023-2024 | Hyqvia, Gammagard |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $143.15 | 2023-2024 | Activa PC, Intellis Adaptivestim, Percept PC Brainsense |
| Globus Medical, INC. | $91.57 | 2025 | Senza, Si-Lok, Senza |
| Ipsen Biopharmaceuticals, INC | $85.39 | 2022-2025 | Dysport |
| Microtransponder, INC. | $83.77 | 2023 | |
| Lundbeck LLC | $82.45 | 2024-2025 | Vyepti, Rexulti |
| Grifols USA, LLC | $78.82 | 2023-2024 | Gamunex-C |
| Alexion Pharmaceuticals, INC. | $76.63 | 2023-2025 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $75.86 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $71.26 | 2022 | |
| Axsome Therapeutics, INC. | $63.84 | 2025 | Symbravo |
| Corium, LLC | $51.58 | 2023 | Adlarity |
| Averitas Pharma INC. | $45.97 | 2024-2025 | Qutenza |
| Insightec,INC | $39.40 | 2023-2024 | Exablate |
| Upsher-Smith Laboratories LLC | $38.04 | 2022-2023 | |
| Supernus Pharmaceuticals, INC. | $32.09 | 2022-2025 | Qelbree |
| Mdd US Operations, LLC | $30.62 | 2025 | Gocovri |
| Si-Bone, INC. | $28.81 | 2025 | |
| Livanova USA, INC. | $27.04 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Astrazeneca Pharmaceuticals LP | $26.68 | 2024 | Andexxa |
| Bioventus LLC | $21.09 | 2025 | Durolane |
| Spr Therapeutics, INC | $20.95 | 2025 | Sprint Pns System |
| Amgen INC. | $20.31 | 2023 | Repatha |
| Azurity Pharmaceuticals, INC. | $19.37 | 2025 | Horizant |
| Orphalan INC | $18.82 | 2025 | Cuvrior |
| Irhythm Technologies, INC. | $17.08 | 2024 | Zio Monitor, Zio Xt Patch |
| Kyowa Kirin, INC. | $14.68 | 2024 | Nourianz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vindhya Koneru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.